FourThought Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

FourThought Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$484K	Buy	1,670 +350	+27%	+$101K	0.07%	182
2022 Q2	$372K	Sell	1,320 -142	-10%	-$38K	0.05%	225
2022 Q1	$379K	Buy	1,462 +213	+17%	+$50.6K	0.05%	238
2021 Q4	$274K	Sell	1,249 -219	-15%	-$42.6K	0.03%	291
2021 Q3	$266K	Buy	1,468 +68	+5%	+$13.3K	0.04%	292
2021 Q2	$282K	Sell	1,400 -137	-9%	-$28.7K	0.04%	297
2021 Q1	$330K	Sell	1,537 -170	-10%	-$37.3K	0.05%	275
2020 Q4	$403K	Buy	+1,707	New	+$392K	0.06%	231

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FourThought Financial's VRTX Position: Q3 2022 in Review

FourThought Financial increased its Vertex Pharmaceuticals (VRTX) stake by 27% in Q3 2022, buying an estimated $101K and bringing the position to 1,670 shares worth $484K. The position accounts for 0.07% of the portfolio, ranked #182.

FourThought Financial first reported a position in VRTX in Q4 2020 and has held it in 8 quarters since. 1,125 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

FourThought Financial held 1,670 shares of Vertex Pharmaceuticals worth $484K as of Q3 2022.
FourThought Financial bought 350 Vertex Pharmaceuticals shares in Q3 2022, an estimated $101K.
Vertex Pharmaceuticals made up 0.07% of FourThought Financial's portfolio in Q3 2022, its #182 holding.
FourThought Financial first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
1,125 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.